[go: up one dir, main page]

BRPI0911634B8 - processo para a preparação de 5-(2-amino-pirimidin-4-il)-2-aril-1h-pirrol-3-carboxamidas - Google Patents

processo para a preparação de 5-(2-amino-pirimidin-4-il)-2-aril-1h-pirrol-3-carboxamidas

Info

Publication number
BRPI0911634B8
BRPI0911634B8 BRPI0911634A BRPI0911634A BRPI0911634B8 BR PI0911634 B8 BRPI0911634 B8 BR PI0911634B8 BR PI0911634 A BRPI0911634 A BR PI0911634A BR PI0911634 A BRPI0911634 A BR PI0911634A BR PI0911634 B8 BRPI0911634 B8 BR PI0911634B8
Authority
BR
Brazil
Prior art keywords
pyrimidin
pyrrole
aryl
amino
carboxamides
Prior art date
Application number
BRPI0911634A
Other languages
English (en)
Inventor
Battistini Carlo
Vanotti Ermes
Gioia Fornaretto Maria
D'anello Matteo
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of BRPI0911634A2 publication Critical patent/BRPI0911634A2/pt
Publication of BRPI0911634B1 publication Critical patent/BRPI0911634B1/pt
Publication of BRPI0911634B8 publication Critical patent/BRPI0911634B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

processo para a preparação de 5-(2-amino-pirimidin-4-il) -2-aril-1h-pirrol-3-carboxamidas a presente i-n-venção se refere a um processo para a preparação de 5-(2-amino-pirimidin-4-il) -2-aril-ih-pirrol-3-carboxamidas e aos compostos interme-diários úteis para este processo. os compostos 5-(2-amino-pirimidin-4-il)-2-aril-lh-pirrol-3-carboxamidas são descritos e reivindicados no documento wo2007110344, que também revela processos para sua preparação. estes compostos podem ser vantajosamente preparados através de um processo que permite obter os produtos desejados com altos rendimentos e pureza e com um número limitado de etapas. a síntese é feita a partir de um derivado ciano pirrol, e é caracterizado a partir da hidrólise final de 5-(2-amino-pirimidin-4-il) -2-aril-lh-pirrol-3-carbonitrila. os compostos preparados de acordo com o processo da presente invenção são dotados de atividade de inibição da proteína quinase e, mais particularmente, inibem a atividade de cdc7 ou cdc7/cdks. os compostos são úteis no tratamento de uma variedade de cânceres, distúrbios de proliferação celular e doenças associadas com proteínas quinases.
BRPI0911634A 2008-04-30 2009-04-30 processo para a preparação de 5-(2-amino-pirimidin-4-il)-2-aril-1h-pirrol-3-carboxamidas BRPI0911634B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08155501 2008-04-30
IT08155501.3 2008-04-30
PCT/EP2009/055262 WO2009133170A1 (en) 2008-04-30 2009-04-30 Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides

Publications (3)

Publication Number Publication Date
BRPI0911634A2 BRPI0911634A2 (pt) 2016-06-14
BRPI0911634B1 BRPI0911634B1 (pt) 2021-05-04
BRPI0911634B8 true BRPI0911634B8 (pt) 2021-05-25

Family

ID=40897697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911634A BRPI0911634B8 (pt) 2008-04-30 2009-04-30 processo para a preparação de 5-(2-amino-pirimidin-4-il)-2-aril-1h-pirrol-3-carboxamidas

Country Status (14)

Country Link
US (1) US8399668B2 (pt)
EP (1) EP2285801B1 (pt)
JP (1) JP5490100B2 (pt)
KR (1) KR20110044835A (pt)
CN (1) CN102036983B (pt)
AU (1) AU2009242076B2 (pt)
BR (1) BRPI0911634B8 (pt)
CA (1) CA2723209C (pt)
EA (1) EA019036B1 (pt)
ES (1) ES2436433T3 (pt)
IL (1) IL208951A0 (pt)
MX (1) MX2010011456A (pt)
TW (1) TWI426074B (pt)
WO (1) WO2009133170A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
ES2552282T3 (es) * 2009-03-27 2015-11-26 Nerviano Medical Sciences S.R.L. Derivados de N-aril-2-(2-arilaminopirimidin-4-il)pirrol-4-carboxamida como inhibidores de la cinasa MPS1
US8592583B2 (en) * 2009-11-04 2013-11-26 Nerviano Medical Sciences Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides
US8658662B2 (en) * 2009-11-11 2014-02-25 Nerviano Medical Sciences S.R.L. Crystalline CDC7 inhibitor salts
TW201127384A (en) * 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
ES2616458T3 (es) * 2011-04-19 2017-06-13 Nerviano Medical Sciences S.R.L. Pirimidil pirroles sustituidos activos como inhibidores de quinasas
US8912200B2 (en) 2011-07-28 2014-12-16 Nerviano Medical Sciences S.R.L. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
IL305087A (en) * 2021-02-12 2023-10-01 Relay Therapeutics Inc CDK inhibitors and methods of using them
KR20230165833A (ko) 2021-04-02 2023-12-05 네르비아노 메디칼 사이언시스 에스.알.엘. 치환된 피롤 카복스아미드, 이의 제조방법 및 이의 키나제 억제제로서의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA805280B (en) * 1979-08-27 1982-04-28 Du Pont Antiinflammatory 4,5-diaryl-a-polyfluoroalkyl-1h-pyrrole-2-methanols and 1-(4,5-diaryl-1h-pyrrol-2-yl)polyfluoralkanones
US5284863A (en) * 1991-12-04 1994-02-08 American Cyanamid Company Haloalkylthio, -sulfinyl and -sulfonyl arylpyrrole fungicidal agents
JPH06135961A (ja) * 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk 新規ジフェニルピロリルフラン誘導体
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0229243D0 (en) * 2002-12-16 2003-01-22 Avecia Ltd Compounds and process
AU2004240772B2 (en) * 2003-05-22 2011-04-28 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
AU2006225700B2 (en) * 2005-03-21 2011-09-01 Eisai R & D Management Co., Ltd. Pyrimidine compound crystal or amorphous form and process for producing the same
MX2008012422A (es) * 2006-03-27 2008-10-09 Nerviano Medical Sciences Srl Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.

Also Published As

Publication number Publication date
ES2436433T3 (es) 2014-01-02
TWI426074B (zh) 2014-02-11
MX2010011456A (es) 2010-11-30
JP5490100B2 (ja) 2014-05-14
CA2723209A1 (en) 2009-11-05
WO2009133170A1 (en) 2009-11-05
BRPI0911634A2 (pt) 2016-06-14
TW200951124A (en) 2009-12-16
HK1151794A1 (en) 2012-02-10
BRPI0911634B1 (pt) 2021-05-04
US20110040090A1 (en) 2011-02-17
CN102036983A (zh) 2011-04-27
CN102036983B (zh) 2014-02-19
KR20110044835A (ko) 2011-05-02
IL208951A0 (en) 2011-01-31
EA201071252A1 (ru) 2011-06-30
AU2009242076B2 (en) 2013-10-10
EP2285801A1 (en) 2011-02-23
EA019036B1 (ru) 2013-12-30
CA2723209C (en) 2016-06-21
US8399668B2 (en) 2013-03-19
AU2009242076A1 (en) 2009-11-05
EP2285801B1 (en) 2013-10-09
JP2011518866A (ja) 2011-06-30

Similar Documents

Publication Publication Date Title
BRPI0911634B8 (pt) processo para a preparação de 5-(2-amino-pirimidin-4-il)-2-aril-1h-pirrol-3-carboxamidas
Grewal Why should cancer biologists care about tRNAs? tRNA synthesis, mRNA translation and the control of growth
MX2011004953A (es) Compuestos utiles como inhibidores de cinasa atr.
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
MX2011006503A (es) Derivados de pirazina utiles como inhibidores de la cinasa de atr.
MY149143A (en) Thiazole compounds as protien kinase b (pkb) inhibitors
JOP20190231A1 (ar) طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MA31571B1 (fr) Composes organiques
IN2014KN02410A (pt)
AU2009306733C1 (en) Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine
MX2012013081A (es) Compuestos utiles como inhibidores de cinasa atr.
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
EP4534538A3 (en) Compounds useful as inhibitors of atr kinase
BR112016006151A2 (pt) imidazopiridazinas úteis como inibidores da via de sinalização do par-2
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0808888B8 (pt) composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
AU2009282962A8 (en) Compounds as kinase inhibitors
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
WO2011143425A3 (en) Compounds useful as inhibitors of atr kinase
MX2012008911A (es) Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
NO20092360L (no) Nye antiproliferasjonsantistoffer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE. PAGAR RESTAURACAO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870160058967 DE 11/10/2016 , EM VIRTUDE DO DISPOSTO NO ARTO 219, INCISO II DA LPI.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2385 DE 20/09/2016

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2825 DE 25-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.